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Abstract: Background The morphology and between-eye symmetry of the visual field loss
associated with the anti-epileptic drug vigabatrin (VAVFL) has received little attention.
Objective To model the appearance, and ensuing staging, of VAVFL, derived with the
European Medicines Agency approved perimetric protocol.
Methods A retrospective, cross-sectional, observational design identified 123 adults
who had received vigabatrin for refractory seizures and who had no evidence of co-
existing retino-geniculo-cortical visual pathway abnormality. Thirty-eight adults with
refractory seizures and identical inclusion criteria, but no exposure to vigabatrin, acted
as controls. For each group, the median outcome at each stimulus location in each eye
(of absolute loss, relative loss or Pattern Deviation probability level, as appropriate)
was derived for each successive ten pairs of fields, ranked for severity. Between-eye
symmetry was quantified by an index which accounted for severity of loss and which
was referenced to the likelihood of the occurrence of symmetry due to chance.
Results The modelled VAVFL was bilateral and highly symmetrical and was described
by six stages which were all independent of the extent of vigabatrin exposure. The loss
originated in the extreme temporal periphery and encroached centripetally along all
meridians towards fixation. The initial appearance within the central field (Stage Two)
occurred inferior-nasally. Subsequent stages exhibited increasing loss which was
greater nasally than temporally. Stage Six described concentric loss extending to
approximately 15° eccentricity from fixation.
Conclusion The model exhibited a consistent pattern of VAVFL. The staging of the loss
could assist the risk:benefit analysis of vigabatrin for the treatment of epilepsy.
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Author Comments: Given the issue with one of the referees of our last manuscript, we would respectfully
insist that the manuscript is NOT refereed by anyone who has previously declared a
conflict of interest with Lundbeck LLC and/ or with Ovation Pharmaceuticals, Inc.
The referees who reviewed the 'appealed' version of our last manuscript were both
interested in, and knowledgeable about, vigabatrin toxicity. Perhaps they could be
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approached again?
Response to Reviewers: CNSA-D-19-00041
Objective derivation of the morphology and staging of visual field loss associated with
long-term vigabatrin therapy
We acknowledge the contribution from each of the reviewers. The review process has
resulted in a much better manuscript.
All changes included in the revised manuscript are highlighted in green and are
described below.
Response to Reviewer #1
1.The subjects are adults. The authors have avoided discussing children but do they
have any sense of whether this data would be of alarm to younger age groups.
We did not ‘avoid(ed) discussing children’. The case series was compiled from adults
on the basis of their ability to perform perimetry.
We have inserted a paragraph in the Discussion at the bottom of page 14/ top of page
15 of the revised manuscript.
The model was developed from the visual fields of adults. The reduction in amplitude of
the 30Hz flicker cone electroretinogram (ERG) in infants treated with vigabatrin for
infantile spasms [31] is compatible with that for adults manifesting VAVFL [32].
Similarly, the topographical characteristics of the reduced peripapillary retinal nerve
fibre layer thickness in children [33] is also compatible with that found in adults [34-38].
Those with vigabatrin-associated 30Hz flicker cone ERG abnormality in infancy
subsequently manifest VAVFL, and corresponding retinal nerve fibre layer thinning, in
later childhood/ early adolescence [39]. There is no reason to suggest, therefore, that
the vigabatrin toxicity manifested in infancy will result in a different appearance to the
VAVFL when the latter measure is obtained in later life.
2.The reader would like to know, just generally, how impaired these subjects were?
Were some in wheelchairs? Head control or eye movement control problem? Any with
frequent seizures e.g., more than a few per day.
The Reviewer seems to have overlooked our commentary at the top of page 17 of the
initial version of the manuscript, namely:
All 14 individuals exhibited impaired mobility and reported symptoms explainable by
their field loss, the most common of which was bumping into individuals in crowded
locations.
Nevertheless, we have modified the paragraph (now top of page 19 of the revised
manuscript). The new text is given in non-italicised text.
All 14 individuals exhibited profoundly impaired mobility and reported symptoms
explainable by their VAVFL, the most common of which was bumping into individuals in
crowded locations. However, some individuals with Stage 5 VAVFL also reported a
negative impact on their activities of daily living.
We have also inserted a sentence in the Methodology at the end of the paragraph on
Page 7
All individuals had been seizure free for a minimum of 24 hours prior to the visual field
examination.
3.I don’t see any data on false-positive and negatives to the field tests – were there
any? This makes it easier to judge the validity of the tests.
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We made reference to the criteria for incorrect responses to the false-positive and
false-negative catch trials the field tests in the initial version of the manuscript (page 7,
middle paragraph).
The reliability criteria comprised ≤20% incorrect responses to the fixation loss catch
trials and ≤15% incorrect responses to the false-positive catch trials. A criterion of
≤30% incorrect responses was used for the false-negative catch trials although this
was widened with increasing severity of the field loss [25].
Accordingly, we have not revised the manuscript in this regard.
4.Do the authors have any data on visible changes to retina morphology that
accompanied the field loss. And if so what stage did these develop.
We have inserted the following in the Discussion from the middle of page 15 onwards
The most common bilateral finding by fundoscopy, through a dilated pupil, was either
generalised or localised arteriolar narrowing which was noted at all stages of VAVFL.
However, this finding was occasionally found in the presence of a normal field and,
therefore, may well be associated with vigabatrin usage. Subtle bilateral retinal nerve
fibre layer changes and optic nerve head pallor were noted from Stage 4 onwards. A
variety of bilateral peripheral degenerative changes were also noted including
hypopigmented/ white spots and surface wrinkling.  However, there was considerable
variation in the fundal appearance between-individuals within a given stage.  The
various features are in agreement with those reported previously [3, 22, 40-41] were
often subtle and suggest that there is a wide spectrum of potential retinopathy
associated with vigabatrin toxicity. There was no evidence of these findings in the
individuals with no exposure to vigabatrin. Twenty-nine individuals exposed to
vigabatrin had undergone optical coherence tomography of the peripapillary retinal
nerve fibre layer at the time of the examination. All three individuals who manifested a
normal visual field exhibited a normal nerve fibre layer thickness.   Of the three
individuals who had Stage 1 loss, two exhibited a normal thickness. An abnormally thin
nerve fibre layer, characteristic of vigabatrin toxicity [34-38], was present from Stage 2
onwards in 22 individuals. The one remaining individual manifested early Stage 2
VAVFL and a normal a normal nerve fibre layer thickness.
5.Were there any other reasons for exclusion…
The exclusion criteria are listed in the methods; no other exclusion criteria were applied
post selection.
6.Do the authors have any sense of what happens if vigabatrin is stopped. Do field
changes continue to progress
Please see the response to Query #1 from Reviewer #2. The following text has been
inserted into the manuscript.
An unpublished audit of the long-term follow-up, over a maximum of eight years, of
individuals in the current study indicates that the field loss neither improves nor
deteriorates following withdrawal of vigabatrin.
Minor change
We have incorporated ‘No’ into the abstract.
Response to Reviewer #2
Major Comments
1.The major weakness of this study is failure to provide data in patients followed up
longitudinally over time. Although the authors imply that patients progress from Stage 1
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(least severe) to Stage 6 (most severe), they have not confirmed that such progression
occurs. Most importantly, how can staging data be interpreted without knowledge of the
probability of progression at each stage, and an estimate of the rate of progression?
These concerns are reinforced by the finding that the occurrence of visual field defects
was related to cumulative dose and duration of treatment, but there was no correlation
between stages and exposure. The authors' comment that toxicity is 'idiosyncratic'
does not explain the lack of correlation between severity of the defect and
dose/duration of exposure. These issues need to be discussed.
We have inserted an essentially new paragraph in the Discussion on Page 17. The
new text is given in non-italicised text.
The staging of VAVFL was derived from cross-sectional evidence and does not imply
progressive loss. Due to the potency of the potential toxicity, most individuals had been
withdrawn from vigabatrin either immediately prior to the introduction of the visual field
examination into the care regime or following confirmation of the VAVFL. As such,
neither the probability of progression at each stage nor an estimate of the rate of
progression can be determined. However, the presumption is that, given continued
vigabatrin therapy, VAVFL will progress through the various stages. The lack of an
association between the stage of loss, at detection, and either the duration or the
cumulative dose of vigabatrin implies that the relationship between the extent of
exposure and both the onset and the severity of VAVFL varies depending upon the
individual susceptibility to vigabatrin. However, the time of detection is not the time to
onset of the VAVFL. The rate of any subsequent progression, therefore, remains
unknown. A case of progressive loss during approximately 7.75 years of vigabatrin
therapy and illustrated in terms of the Pattern Deviation probability map of the Central
24-2 Threshold Test and, subsequently, the C30-2T is shown in Fig 6. The outcome of
the corresponding FF135 at the final visit is shown in Online Resource Fig 4. VAVFL
has also been shown to be progressive whilst on therapy in all 14 cases over a mean
follow-up of 10.7 years with the rate of reduction in the I4e isopter of kinetic perimetry
increasing with increase in cumulative dose [6]. An unpublished audit of the long-term
follow-up, over a maximum of eight years, of individuals in the current study indicates
that VAVFL neither improves nor deteriorates following withdrawal of vigabatrin.
2.Selection bias
We have inserted a sentence relating to selection bias in the last sentence on Page 6.
There was no conscious selection bias. Patients were included on the basis of
sequential retrieval of cases which met the inclusion/ exclusion criteria.
3.Continuity in severity of field loss across stages. How were cutoffs across stages
(and the actual number of stage) defined?
We have modified the paragraph (now at the bottom of page 9/ top of page 10 of the
revised manuscript). The new text is given in non-italicised text.
The stages were empirically selected on the basis of clinically meaningful intervals of
peripheral field loss and, subsequently, of central field loss. These intervals, in turn,
were based upon the magnitude of the between-examination physiological variability in
the differential light sensitivity as a function of severity of loss [28-29].   The derivation
ensured continuity across stages.
4.Please clarify whether the ophthalmologist was aware of the exposure status.
We have inserted a commentary on page 15.
The ophthalmological examinations were undertaken by any one of four
ophthalmologists, depending upon the particular clinic, who were all unaware of the
findings from their colleagues. All four were aware of the anti-epileptic drug history and,
usually, of the visual field. However, the modelling of the visual fields from those
exposed to vigabatrin and from the control individuals was objective and independent
of the outcome from the ophthalmological and neurological examinations.
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Compile Table about characteristics/ Statistical differences
We have inserted the summary statistics for the duration and cumulative dose of
vigabatrin into the penultimate paragraph on page 12 of the revised manuscript.
Those with VAVFL manifested a greater cumulative dose (mean 7.94kg; SD 4.45;
range 1.1 to 20.7) and a longer duration of therapy (8.86 years; SD 3.51; range 0.66 to
16.05) at the time of perimetry than those without field loss (mean 3.36kg; SD 4.77;
range 0.11 to 16.14;  and mean 3.62 years; SD 3.94; range 0.33 to 11.83;
respectively). The difference between means (Student’s t-test for two independent
samples) were 4.58 kg (95% CI 1.71-7.45; p<0.001) and 5.25 years (95% CI 2.98-7.53;
p<0.001), respectively.
We have inserted and additional sentence on Page 12.
There was no association between the stage of VAVFL and either age, age at onset of
epilepsy or age at onset of vigabatrin.
Minor Comments
1.Remove without prescription
The statement concerning the free availability on-line without prescription has been
removed from the revised manuscript
2.Lines 26-50 This paragraph does not describe appropriately the background for the
study.
The Reviewer is incorrect in his/ her commentary.
i)The best description of the methodology used to compile the Registry described by
Krauss et (2016) is that of Pellock et al (2011) [Epilepsy & Behavior 2011;22:710-717].
Page 2 Paragraph 4 of Pellock et al (2011) states that:
‘Regular ophthalmologic assessments are required throughout vigabatrin therapy: at
baseline (≤4 weeks after therapy initiation), at least every 3 months during therapy and
3 to 6 months after discontinuation. Fulfilment of this mandate is documented by
registry receipt of an ophthalmologic assessment form…………In many instances, the
first actual vision test may be conducted well after entry into the registry.’
The Registry was an FDA mandated requirement for the marketing authorisation of
Sabril within the USA.  The data analysis for the Krauss et al (2016) paper was
undertaken by a third party institution and the editorial support for the paper was
funded by the Marketing Authorisation Holder for Sabril in the USA. The paper is
carefully worded, is ambiguous in crucial places, and largely concentrates on the
number of individuals enrolled within the Registry and the likelihood of retention of
these individuals over time. The referee is correct in his/ her assertion that the paper by
Krauss et al (2016) ‘does not provide (sic) baseline data on visual fields’; however, the
paper states that:
‘Clinicians reported that eight patients discontinued treatment because of visual field
defects (VFD). The patients ranged from ages 18 to 55 years at entry into the SHARE
program and were divided equally by gender. One 19 year old patient was reported to
have an indication of IS, the other patients had CPS. Three patients entered the
program with previous vigabatrin exposure. The five patients who were newly treated
had vigabatrin discontinued by their clinicians because of VFD after exposures of 13
months to 3.3 years (Mean: 23 months).’
T
he clear implication from the above is that the visual field loss in at least five patients
occurred after the baseline examination.
There is no discussion in the paper on the (low) prevalence of visual field loss and no
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mention of the fact that ‘the data are not interpreted as indicating lack of visual toxicity.’
Although not stated, the clear implication to the reader is that the prevalence of the
toxicity, derived from a [this] prospective study, is much lower than that derived from
the (European) retrospective studies.
ii)The Sergott et al (2016) paper is described as a ‘small study sponsored by
Lundbeck.’  It should be noted that this study was a one year prospective study was
mandated by the FDA.
Given the above and given the acceptance by Reviewer #1, we have not altered the
paragraph.
  Response to Comments from Editor
1.We have moved the definition of VAVFL to the end of the figure legend
2.We have renumbered the figures as advised
3.We have revised the format of the supplementary content as advised
Our preference would be to embed a link to the videos within the article.
Suggested Reviewers: Mark Lawden, PhD, FRCP
Consultant Neurologist, University Hospitals Of Leicester NHS Trust
mark.lawden@uhl-tr.nhs.co.uk
International authority on vigabatrin toxicity
Emilio Perruca, MD, PhD
Professor. Director, University of Pavia. IRCCS. Mondino National Neurological
Institute in Pavia
perucca@unipv.it
International reputation for the neurology and clinical pharmacology of epilepsy
James Acheson, FRCOPhth, FRCP
National Hospital for Neurology and Neurosurgery and Moorfields Eye Hospital,
London
james.acheson@nhs.net
Internationally renown clinical neuro-ophthalmologist with an interest in vigabatrin
toxicity
Lars Frisen, MD
Institute of Neuroscience and Physiology, University of Gothenburg
lars.frisen@neuro.gu.se
Internationally acclaimed neuro-ophthalmologist with a knowledge of vigabatrin toxicity
Ivan Goldberg, MD
Professor, University of Sydney
ivan.goldberg@sydney.edu.au
Internationally acclaimed ophthalmologist with a special interest in perimetry
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Sue Pochon 
Editor 
CNS drugs 
 
22nd February 2019 
 
Dear Sue 
 
As promised in an earlier email relating to our last manuscript on vigabatrin (which is now published 
in CNS Drugs), please find uploaded a new manuscript entitled: 
 
 
Objective derivation of the morphology and staging of visual field loss 
associated with long-term vigabatrin therapy 
 
 
which we hope will be found suitable for publication in CNS Drugs. 
 
 
The manuscript is particularly aimed at neurologists, neuro-ophthalmologists, general 
ophthalmologists and other healthcare workers associated with the care of patients with epilepsy.  
 
 
Due to the cross-discipline nature of the topic, and given our past publications in the journal, we feel 
that CNS Drugs is the most appropriate setting for the above readership. 
 
 
As you know vigabatrin is a highly effective drug for the treatment of refractory focal seizures but, 
for almost two decades, has been associated with visual field loss and with various other retinal/ 
optic nerve structural and functional abnormalities.  
 
Inexplicably, the appearance of vigabatrin-associated visual field loss (VAVFL) has never been 
illustrated/ described in detail.  
 
 
The manuscript is topical in that: 
 
 The use of vigabatrin is likely to increase, given  
 
Cover Letter
 
 
o the apparent lack of evidence for the toxicity arising from the two recent 
prospective studies (but these only involved short-term exposures)  
 
o the drug has recently become available as a generic  
 
o the drug is also freely obtainable on-line without prescription 
 
 
 
The manuscript is novel in that it:  
 
 Presents the first ever staging of VAVFL 
 
o the staging is based upon an objective model derived from signal-to-noise 
processing, the technique of which, in itself, is novel 
 
the modelling could also be applied to other types of visual field loss arising from 
drug toxicity  
 
o the field loss is recorded with a widely available, and regulatory authority approved, 
perimetric protocol 
 
  
 Presents the first quantitative description of the inter-ocular mirror symmetry of VAVFL  
 
o the technique for quantifying symmetry has not been described before and could also 
be applied to other types of visual field loss 
 
 
 Is based upon long-term usage of vigabatrin (median 8.8 years; IQR 5.7 to 11.3; range 0.33 to 
16.1); many of these long-term exposures are unprecedented in the literature 
 
 
 Contains the first illustration of a case of progressive VAVFL obtained (over a seven year 
period) by standard automated perimetry. 
 
 The modelled fields from those exposed to vigabatrin are illustrated as videos in Online Resource 
Videos 1 2, and 3 respectively, and from the control individuals in Online Resource Video 4.  
 
 
 
  
o these videos are the product of sophisticated computational  
methodologies 
 
o the use of such a presentation to illustrate the appearance of the  
visual field is, to our knowledge, a first  for any journal 
 
o the use of video material is also a first for CNS Drugs 
 
 
The Online Resource Video files form the basis of the manuscript and it is essential that each referee 
is able to view the content of these files. 
 
 
Given the issue with one of the referees of our last manuscript, we would respectfully insist that 
the manuscript is NOT refereed by anyone who has previously declared a conflict of interest with 
Lundbeck LLC and/ or with Ovation Pharmaceuticals, Inc.  
 
 
Best wishes. 
 
 
Yours Sincerely, 
   
John Wild 
 
 
John Wild 
CNSA-D-19-00041 
 
Objective derivation of the morphology and staging of visual field loss associated with long-term 
vigabatrin therapy 
 
We acknowledge the contribution from each of the reviewers. The review process has 
resulted in a much better manuscript. 
 
All changes included in the revised manuscript are highlighted in green and are described 
below. 
 
Response to Reviewer #1 
 
1. The subjects are adults. The authors have avoided discussing children but do they 
have any sense of whether this data would be of alarm to younger age groups. 
We did not ‘avoid(ed) discussing children’. The case series was compiled from adults on the 
basis of their ability to perform perimetry.  
We have inserted a paragraph in the Discussion at the bottom of page 14/ top of page 15 of the 
revised manuscript. 
The model was developed from the visual fields of adults. The reduction in amplitude of the 
30Hz flicker cone electroretinogram (ERG) in infants treated with vigabatrin for fantile spasms 
[31] is compatible with that for adults manifesting VAVFL [32]. Similarly, the topographical 
characteristics of the reduced peripapillary retinal nerve fibre layer thickness in children [33] is 
also compatible with that found in adults [34-38]. Those with vigabatrin-ssociated 30Hz flicker 
cone ERG abnormality in infancy subsequently manifest VAVFL, and corresponding retinal 
nerve fibre layer thinning, in later childhood/ early adolescence [39]. There is no reason to 
suggest, therefore, that the vigabatrin toxicity manifested in infancy will result in a different 
appearance to the VAVFL when the latter measure is obtained in later life. 
 
2. The reader would like to know, just generally, how impaired these subjects were? 
Were some in wheelchairs? Head control or eye movement control problem? Any 
with frequent seizures e.g., more than a few per day. 
The Reviewer seems to have overlooked our commentary at the top of page 17 of the initial 
version of the manuscript, namely:  
All 14 individuals exhibited impaired mobility and reported symptoms explainable by their field 
loss, the most common of which was bumping into individuals in crowded locations. 
Nevertheless, we have modified the paragraph (now top of page 19 of the revised manuscript). The 
new text is given in non-italicised text. 
All 14 individuals exhibited profoundly impaired mobility and reported symptoms explainable 
by their VAVFL, the most common of which was bumping into individuals in crowded locations. 
However, some individuals with Stage 5 VAVFL also reported a negative impact on their 
activities of daily living. 
Author's Response to Comments Click here to access/download;Author’s Response to
Comments;CNS_staging_Response_v6.docx
We have also inserted a sentence in the Methodology at the end of the paragraph on Page 7 
All individuals had been seizure free for a minimum of 24 hours prior to the visual field 
examination. 
 
3. I don’t see any data on false-positive and negatives to the field tests – were there any? 
This makes it easier to judge the validity of the tests.  
We made reference to the criteria for incorrect responses to the false-positive and false-negative catch 
trials the field tests in the initial version of the manuscript (page 7, middle paragraph). 
The reliability criteria comprised ≤20% incorrect responses to the fixation loss catch trials and ≤15% 
incorrect responses to the false-positive catch trials. A criterion of ≤30% incorrect responses was 
used for the false-negative catch trials although this was widened with increasing severity of the 
field loss [25]. 
Accordingly, we have not revised the manuscript in this regard. 
 
4. Do the authors have any data on visible changes to retina morphology that 
accompanied the field loss. And if so what stage did these develop. 
We have inserted the following in the Discussion from the middle of page 15 onwards 
The most common bilateral finding by fundoscopy, through a dilated pupil, was either generalised 
or localised arteriolar narrowing which was noted at all stages of VAVFL. However, this finding 
was occasionally found in the presence of a normal field and, therefore, may well be associated with 
vigabatrin usage. Subtle bilateral retinal nerve fibre layer changes and optic nerve head pallor were 
noted from Stage 4 onwards. A variety of bilateral peripheral degenerative changes were also noted 
including hypopigmented/ white spots and surface wrinkling.  However, th e was considerable 
variation in the fundal appearance between-individuals within a given stage.  The various features 
are in agreement with those reported previously [3, 22, 40-41] were often subtle and suggest that 
there is a wide spectrum of potential retinopathy associated with vigabatrin toxicity. There was no 
evidence of these findings in the individuals with no exposure to vigabatrin. Twenty-nine individuals 
exposed to vigabatrin had undergone optical coherence tomography of the peripapilla y retinal nerve 
fibre layer at the time of the examination. All three individuals who manifested a normal visual field 
exhibited a normal nerve fibre layer thickness.   Of the three individuals who had Stage 1 loss, two 
exhibited a normal thickness. An abnormally thin nerve fibre layer, characteristic of vigabatrin 
toxicity [34-38], was present from Stage 2 onwards in 22 individuals. The one remaining individual 
manifested early Stage 2 VAVFL and a normal a normal nerve fibre layer thickness. 
 
5. Were there any other reasons for exclusion… 
The exclusion criteria are listed in the methods; no other exclusion criteria were applied post 
selection.  
 
6. Do the authors have any sense of what happens if vigabatrin is stopped. Do field 
changes continue to progress 
Please see the response to Query #1 from Reviewer #2. The following text has been inserted into the 
manuscript. 
An unpublished audit of the long-term follow-up, over a maximum of eight years, of individuals in 
the current study indicates that the field loss neither improves nor deteriora s following withdrawal 
of vigabatrin. 
 
 
Minor change 
 
We have incorporated ‘No’ into the abstract.  
 
 
Response to Reviewer #2  
 
Major Comments 
 
1. The major weakness of this study is failure to provide data in patients followed up 
longitudinally over time. Although the authors imply that patients progress from Stage 
1 (least severe) to Stage 6 (most severe), they have not confirmed that such progression 
occurs. Most importantly, how can staging data be interpreted without knowledge of 
the probability of progression at each stage, and an estimate of the rate of progression?  
These concerns are reinforced by the finding that the occurrence of visual field defects 
was related to cumulative dose and duration of treatment, but there was no correlation 
between stages and exposure. The authors' comment that toxicity is 'idiosyncratic' 
does not explain the lack of correlation between severity of the defect and 
dose/duration of exposure. These issues need to be discussed. 
 
 
We have inserted an essentially new paragraph in the Discussion on Page 17. The new text is given in non-
italicised text. 
The staging of VAVFL was derived from cross-sectional evidence and does not imply progressive 
loss. Due to the potency of the potential toxicity, most individuals had been withdrawn from 
vigabatrin either immediately prior to the introduction of the visual field examination into the care 
regime or following confirmation of the VAVFL. As such, neither the probability of progression at 
each stage nor an estimate of the rate of progression can be determined. How ver, the presumption 
is that, given continued vigabatrin therapy, VAVFL will progress through the various stages. The 
lack of an association between the stage of loss, at detection, and either the duration or the 
cumulative dose of vigabatrin implies that the relationship between the extent of exposure and both 
the onset and the severity of VAVFL varies depending upon the individual susceptibility to 
vigabatrin. However, the time of detection is not the time to onset of the VAVFL. The rate of any 
subsequent progression, therefore, remains unknown. A case of progressive loss during 
approximately 7.75 years of vigabatrin therapy and illustrated in terms of the Pattern Deviation 
probability map of the Central 24-2 Threshold Test and, subsequently, the C30-2T is shown in Fig 
6. The outcome of the corresponding FF135 at the final visit is shown in Online Resource Fig 4. 
VAVFL has also been shown to be progressive whilst on therapy in all 14 cases over a mean follow-
up of 10.7 years with the rate of reduction in the I4e isopter of kinetic perimetry increasing with 
increase in cumulative dose [6]. An unpublished audit of the long-term follow-up, over a maximum 
of eight years, of individuals in the current study indicates that VAVFL neither improves nor 
deteriorates following withdrawal of vigabatrin. 
  
 
2. Selection bias 
We have inserted a sentence relating to selection bias in the last sentence on Page 6. 
 There was no conscious selection bias. Patients were included on the basis of sequential retrieval 
of cases which met the inclusion/ exclusion criteria. 
 
3. Continuity in severity of field loss across stages. How were cutoffs across stages (and 
the actual number of stage) defined? 
We have modified the paragraph (now at the bottom of page 9/ top of page 10 of the revised manuscript). 
The new text is given in non-italicised text. 
The stages were empirically selected on the basis of clinically meaningful intervals of peripheral 
field loss and, subsequently, of central field loss. These intervals, in turn, were based upon the 
magnitude of the between-examination physiological variability in the differential light sensitivity 
as a function of severity of loss [28-29].   The derivation ensured continuity across stages. 
 
4. Please clarify whether the ophthalmologist was aware of the exposure status. 
 We have inserted a commentary on page 15. 
The ophthalmological examinations were undertaken by any one of four ophthalmologists, 
depending upon the particular clinic, who were all unaware of the findings from their colleagues. 
All four were aware of the anti-epileptic drug history and, usually, of the visual field. However, the 
modelling of the visual fields from those exposed to vigabatrin and from the control individuals was 
objective and independent of the outcome from the ophthalmological and neurological 
examinations.  
 
Compile Table about characteristics/ Statistical differences  
We have inserted the summary statistics for the duration and cumulative dose of vigabatrin into the 
penultimate paragraph on page 12 of the revised manuscript. 
Those with VAVFL manifested a greater cumulative dose (mean 7.94kg; SD 4.45; range 1.1 to 20.7) and a 
longer duration of therapy (8.86 years; SD 3.51; range 0.66 to 16.05) at the time of perimetry than those without 
field loss (mean 3.36kg; SD 4.77; range 0.11 to 16.14;  and mean 3.62 years; SD 3.94; range 0.33 to 11.83; 
respectively). The difference between means (Student’s t-test for two independent samples) were 4.58 kg (95% 
CI 1.71-7.45; p<0.001) and 5.25 years (95% CI 2.98-7.53; p<0.001), respectively.  
 
We have inserted and additional sentence on Page 12.  
 
There was no association between the stage of VAVFL and either age, age at ons t of epilepsy or age at onset of 
vigabatrin. 
 
 
 
Minor Comments 
 
1. Remove without prescription 
The statement concerning the free availability on-line without prescription has been removed 
from the revised manuscript 
 
2. Lines 26-50 This paragraph does not describe appropriately the background for the 
study. 
 
The Reviewer is incorrect in his/ her commentary. 
 
i) The best description of the methodology used to compile the Registry described by 
Krauss et (2016) is that of Pellock et al (2011) [Epilepsy & Behavior 2011;22:710-
717]. 
  
Page 2 Paragraph 4 of Pellock et al (2011) states that: 
 
‘Regular ophthalmologic assessments are required throughout vigabatrin therapy: at baseline 
(≤4 weeks after therapy initiation), at least every 3 months during therapy and 3 to 6 months 
after discontinuation. Fulfilment of this mandate is documented by registry receipt of an 
ophthalmologic assessment form…………In many instances, the first actual vision test may be 
conducted well after entry into the registry.’  
 
The Registry was an FDA mandated requirement for the marketing authorisation of Sabril 
within the USA.  The data analysis for the Krauss et al (2016) paper was undertaken by a 
third party institution and the editorial support for the paper was funded by the Marketing 
Authorisation Holder for Sabril in the USA. The paper is carefully worded, is ambiguous in 
crucial places, and largely concentrates on the number of individuals enrolled within the 
Registry and the likelihood of retention of these individuals over time. The referee is correct 
in his/ her assertion that the paper by Krauss et al (2016) ‘does not provide (sic) baseline 
data on visual fields’; however, the paper states that:  
 
‘Clinicians reported that eight patients discontinued treatment because of visual field defects 
(VFD). The patients ranged from ages 18 to 55 years at entry into the SHARE program and 
were divided equally by gender. One 19 year old patient was reported to have an indication of 
IS, the other patients had CPS. Three patients entered the program with previous vigabatrin 
exposure. The five patients who were newly treated had vigabatrin discontinued by their 
clinicians because of VFD after exposures of 13 months to 3.3 years (Mean: 23 months).’  
The clear implication from the above is that the visual field loss in at least five patients 
occurred after the baseline examination.  
There is no discussion in the paper on the (low) prevalence of visual field loss and no 
mention of the fact that ‘the data are not interpreted as indicating lack of visual toxicity.’  
Although not stated, the clear implication to the reader is that the prevalence of the 
toxicity, derived from a [this] prospective study, is much lower than that derived from the 
(European) retrospective studies.  
 
ii) The Sergott et al (2016) paper is described as a ‘small study sponsored by Lundbeck.’  
It should be noted that this study was a one year prospective study was mandated by 
the FDA. 
 
Given the above and given the acceptance by Reviewer #1, we have not altered the paragraph. 
 
  Response to Comments from Editor 
 
1. We have moved the definition of VAVFL to the end of the figure legend 
2. We have renumbered the figures as advised 
3. We have revised the format of the supplementary content as advised 
 
Our preference would be to embed a link to the videos within the article. 
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Abstract 
Background The morphology and between-eye symmetry of the visual field loss associated with 
the anti-epileptic drug vigabatrin (VAVFL) has received little attention. 
Objective To model the appearance, and ensuing staging, of VAVFL, derived with the European 
Medicines Agency approved perimetric protocol. 
Methods A retrospective, cross-sectional, observational design identified 123 adults who had 
received vigabatrin for refractory seizures and who had no evidence of co-existing retino-
geniculo-cortical visual pathway abnormality. Thirty-eight adults with refractory seizures and 
identical inclusion criteria, but no exposure to vigabatrin, acted as controls. For each group, the 
median outcome at each stimulus location in each eye (of absolute loss, relative loss or Pattern 
Deviation probability level, as appropriate) was derived for each successive ten pairs of fields, 
ranked for severity. Between-eye symmetry was quantified by an index which accounted for 
severity of loss and which was referenced to the likelihood of the occurrence of symmetry due to 
chance.  
Results The modelled VAVFL was bilateral and highly symmetrical and was described by six 
stages which were all independent of the extent of vigabatrin exposure. The loss originated in the 
extreme temporal periphery and encroached centripetally along all meridians towards fixation. 
The initial appearance within the central field (Stage Two) occurred inferior-nasally. Subsequent 
stages exhibited increasing loss which was greater nasally than temporally. Stage Six described 
concentric loss extending to approximately 15° eccentricity from fixation.  
Conclusion The model exhibited a consistent pattern of VAVFL. The staging of the loss could 
assist the risk:benefit analysis of vigabatrin for the treatment of epilepsy. 
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Key Points 
 
In this study of 123 individuals treated with vigabatrin as adjunct therapy for refractory focal 
seizures and without evidence of other retino-geniculo-cortical visual pathway abnormality, 
objective modelling, based upon convolution theory used in signal-to-noise processing, 
identified a consistent pattern of bilateral symmetrical visual field loss obtained using a 
regulatory approved perimetric protocol. No modelled field loss was present for the 38 
individuals with identical inclusion criteria but no exposure to vigabatrin.    
Six stages of modelled vigabatrin-associated field loss (VAVFL) were evident. Originating in 
the extreme temporal periphery, the field loss encroached, with increasing severity, 
centripetally along all meridians towards fixation with greater nasal than temporal loss. Stage 
Six manifested as concentric loss to within approximately 15° from fixation.  
The between-eye mirror symmetry of the VAVFL at all stages, quantified by a novel index, 
which accounted for the severity of loss, was not attributable to chance (p≤0.01). 
The use of either the Central 30-2 or the Central 24-2 Threshold Tests, alone, will not identify 
VAVFL until late Stage Two and late Stage Three, respectively.  
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1.0 Introduction 
The anti-epileptic drug vigabatrin has long been associated with visual field loss (VAVFL) [1-2] 
which manifests as a bilateral concentric peripheral defect over a continuum of severity and 
which, generally, also involves the central field to varying extents [3-4]. The field loss is 
considered to be slowly progressive [5-7] irreversible but non-progressive on withdrawal from 
vigabatrin [8-9] and asymptomatic until severe loss is present [3, 10-12]. The modelled 
prevalence of VAVFL in adults increases rapidly after the first two years (2kg cumulative dose) 
of exposure [13-14]  and can reach 75-80% after approximately six years (5kg cumulative dose) 
[14]. Vigabatrin is now available generically.   
 
The association between vigabatrin and ocular toxicity is currently being re-evaluated [15-17] on 
the basis that the attribution of the toxicity emanates from retrospective studies which do not 
include a pre-treatment baseline evaluation. The lack of evidence for the toxicity in the two 
prospective studies alongside the finding that approximately 25% of individuals suitable for 
vigabatrin exhibited clinically significant pre-existing reduced visual acuity and/ or visual field 
loss and/ or peripapillary retinal nerve fibre layer thinning, has led to the suggestion that 
abnormalities of the afferent system are a co-morbidity of severe refractory epilepsy and are 
unrelated to vigabatrin [15-16]. However, the limited exposures to vigabatrin and the poor 
retention of individuals, within these two studies [15-16], together with inappropriate visual field 
methodologies and analyses, have not facilitated detection of the toxicity.   
 
Surprisingly, there has been little emphasis on the areal and depth characteristics, the between 
eye-symmetry, and the staging, of VAVFL.  Such information is essential not only to identify the 
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onset and the progression of the VAVFL but also to differentiate it from other types of 
(concomitant) field loss.  
 
The areal extent and the depth of any type of visual field loss is highly dependent upon the 
perimetric technique used for the examination. VAVFL has been investigated by a variety of 
methods [7, 10-11, 16, 18-23] but the characteristics of the field loss by each technique have 
received little attention. Unfortunately, due to the peripheral nature of the field loss, there is no 
one ideal technique, across the current range of commercially available perimeters, for the 
assessment of VAVFL. The most pragmatic approach is that approved by the European 
Medicines Agency (EMA) [23] namely, Three Zone (two luminance level) suprathreshold 
perimetry, referenced to the age-corrected threshold, of the peripheral field out to a maximum 
temporal extent of 90° eccentricity and standard automated perimetry of the central field (SAP).  
 
Given the on-going re-evaluation of the association between vigabatrin and visual field loss and 
the wider availability of the drug, a description of the morphology and staging of the VAVFL 
resulting from the EMA approved protocol, and derived from individuals with long-term 
exposures to vigabatrin, would be of benefit to clinicians and to patients, alike. If such a 
description was based upon a technique which reduced the signal-to-noise ratio and was derived 
from individuals with no evidence of retino-geniculo-cortical visual pathway abnormality, except 
that of potential vigabatrin toxicity, the characteristics of the field loss attributable to vigabatrin 
would become manifest from backgrounds of any unexpected field loss and of any increased 
variability associated with the response by the patient. Such an approach would also enable the 
use of the visual fields from individuals with long-term exposures to vigabatrin but with no pre-
treatment baseline.  
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The aim of the study, therefore, was threefold: to model the morphology of VAVFL obtained 
with the EMA approved perimetric protocol and resulting from long-term vigabatrin therapy; to 
quantify any between-eye symmetry; and to describe the ensuing staging of the field loss. 
 
2.0 Methods 
 
2.1 Case series 
A retrospective case series comprising 161 adults with refractory complex partial (focal) seizures 
was compiled from those presenting to the Alan Richens Unit of the Welsh Epilepsy Centre, 
University Hospital of Wales, Cardiff, UK, and to associated clinics. All individuals had 
undergone part or all of the EMA approved protocol with the Humphrey Field Analyzer 750 
(Carl Zeiss, Meditec, Dublin, CA) namely, the Full Field 135 Point Test with the three zone age-
corrected strategy (FF135) and the Central 30-2 Threshold Test (C30-2T) with the FASTPAC 
strategy. None exhibited ocular or intra-cranial conditions resulting in, or likely to cause, visual 
field loss, as determined by ophthalmological and neurological examination including whole-
brain magnetic resonance imaging. Further exclusion criteria comprised the presence of 
structural and/or functional ocular abnormalities likely to impede or confound the outcome of 
perimetry and which are described elsewhere [24]. There was no conscious selection bias. 
Individuals were included on the basis of sequential retrieval of cases which met the inclusion/ 
exclusion criteria.  
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2.2 Vigabatrin exposure  
Of the 161 individuals (Fig 1, top row), 123 had been exposed to vigabatrin as add-on therapy. 
The remaining 38 individuals had received a variety of other antiepileptic drugs and were 
included as age-matched controls.  
 
2.3 Perimetry 
Sixty-three of the 123 individuals exposed to vigabatrin and all 38 of those exposed to other 
antiepileptic drugs had undergone the complete EMA approved protocol (Fig 1, second row). Of 
the remaining 60 individuals exposed to vigabatrin, 24 had undergone the FF135, only, and 36 
had undergone the C30-2T, only (Fig 1, second row) as ordered by the treating neurologist on 
clinical grounds. Thus, 87 of the 123 individuals exposed to vigabatrin had undertaken the 
FF135 and 99 individuals had undertaken the C30-2T.  
 
The visual fields from the first occasion, after the first visit, at which reliable perimetric 
outcomes had been achieved were used for the individuals in each of the two groups. The 
reliability criteria comprised ≤20% incorrect responses to the fixation loss catch trials and ≤15% 
incorrect responses to the false-positive catch trials. A criterion of ≤30% incorrect responses was 
used for the false-negative catch trials although this was widened with increasing severity of the 
field loss [25]. All individuals had been seizure free for a minimum of 24 hours prior to the 
visual field examination. 
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2.4 Morphology of visual field loss 
The Single Field Printouts of the FF135 and of the C30-2T were exported to a personal computer 
via a Humphrey Field Analyzer 820 and saved in Tagged Image File Format. The outputs from 
each eye for both types of perimetry were then read by custom Naïve Bayesian character 
recognition software [26].  
 
The fields were separately sorted for each group, and for each type of perimetry, as right and left 
eye pairs, and ranked from the least to the most affected field. The severity of the given pair of 
fields was defined as the sum, across the two eyes, of the number of defects, weighted to account 
for relative or absolute loss, respectively, derived by the FF135 and/ or for the probability level 
of the Pattern Deviation probability map derived by the C30-2T. In the case of those undergoing 
both tests, the outcome from the C30-2T was more heavily weighted.  
 
The median outcome for each group at each stimulus location in each eye for each type of 
perimetry was then separately calculated for each successive ten pairs of fields, ranked for 
severity. Such an approach was based upon convolution theory used in signal processing [27].  
The procedure resulted in 54 pairs of modelled fields from the 63 individuals exposed to 
vigabatrin who had undergone the combined EMA protocol; 78 pairs for the FF135 and 90 for 
the C30-2T.  Twenty-nine pairs of modelled fields resulted from the 38 individuals with no 
vigabatrin exposure.  The outcomes for the right and left eyes, separately, were then displayed in 
terms of Audio Video Interleaved (AVI) movies. 
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2.5 Between-eye mirror symmetry of visual field loss 
The between-eye mirror symmetry of the field was expressed in terms of a single index which 
comprised two components, each of which was a fraction. The index accounted for the severity 
of loss and was compared to the likelihood of obtaining symmetrical field loss due to chance. 
The numerator and denominator of the first component constituted of, respectively, the number 
of mirror image stimulus locations between the two eyes which exhibited either relative or 
absolute loss for the FF135, or abnormality at p≤0.02 by Pattern Deviation probability analysis 
for the C30-2T, and the total number of locations exhibiting abnormality across the two eyes. 
The numerator and denominator of the second component comprised, respectively, the total 
number of locations exhibiting abnormality across the two eyes and the total number of stimulus 
locations across the two eyes.  The index was compared to that obtained from the simulation of 
one million randomly generated pairs of abnormal fields which manifested varying locations, 
areas and depths of field loss both within- and between-eyes. The concept was such that 
symmetry would become apparent when compared to a series of pairs of fields with varying 
characteristics of asymmetric field loss.  
 
The symmetry index was separately calculated for each pair of peripheral, and each pair of 
central fields, for the modelled fields and for the measured fields.  
 
2.6 Staging of the measured fields for those exposed to vigabatrin 
The staging of the VAVFL was derived from the modelled fields. The stages were empirically 
selected on the basis of clinically meaningful intervals of peripheral field loss and, subsequently, 
of central field loss. These intervals, in turn, were based upon the magnitude of the between-
examination physiological variability in the differential light sensitivity as a function of severity 
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of loss [28-29].   The derivation ensured continuity across stages. The staging of the modelled 
peripheral fields was undertaken masked to that of the modelled central fields. The outcome of 
the staging of the central and peripheral fields, with respect to one another, was then validated 
based upon the outcome of the model from the individuals who had undergone the combined 
protocol. The staging was then applied to each of the 87 pairs of measured fields from the FF135 
and to each of the 99 measured fields from the C30-2T. 
 
3.0 Results 
 
3.1 Demographic characteristics of the case series 
Of the 123 individuals exposed to vigabatrin, 50 were male and 73 female. Thirty-five were 
receiving vigabatrin at the time of perimetry. Of the 38 age-matched controls, 17 were male 
and 21 female. The mean ages of the two groups, at the time of perimetry, were 40.8 years 
(SD 13.6) and 38.5 years (SD 10.0), respectively. 
 
3.2 Morphology of VAVFL 
The rolling medians of the 78 pairs of modelled fields for the FF135 from those exposed to 
vigabatrin; of the 90 pairs for the C30-2T; and of the 54 pairs for the combined EMA 
protocol are given in video format in Online Resource Figs 1, 2 and 3, respectively (available 
from URL: https://doi.org/10.6084/m9.figshare.7981592).  
 
The rolling medians of the 29 pairs of modelled fields for the combined EMA protocol from 
those with no exposure to vigabatrin are given in video format in Online Resource Fig 4 
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(available from URL: https://doi.org/10.6084/m9.figshare.7981592).  The modelled fields showed 
was no evidence of visual field loss.  
3.3 Staging of VAVFL 
The staging of the FF135 and of the C30-2T modelled fields for those exposed to vigabatrin 
is shown in Figs 2 to 4.  
 
Sixteen of the 36 individuals exposed to vigabatrin, who had undergone the C30-2T, only, 
manifested a normal measured central field (Fig 1 third row). These 16 fields were included 
in the model, but, in the absence of a peripheral field assessment, the individuals could not be 
categorised as to the potential outcome of the toxicity and were considered as equivocal.   
 
Of the remaining 107 individuals exposed to vigabatrin (Fig 1, fourth row), 12 exhibited 
normal measured fields and 95 field loss which conformed to the modelled fields and which 
was therefore designated as VAVFL.  
 
The frequency, by stage, of VAVFL is shown in Fig 1 (bottom row). Fourteen of the 95 
individuals with VAVFL exhibited Stage One VAVFL, 21 Stage Two, 14 Stage Three, 22 
Stage Four, 10 Stage Five and 14 Stage Six.  
 
The relationship between the stage of loss and the summary measures of the visual field, 
Mean Deviation (MD) and Pattern Standard Deviation, for the C30-2T measured fields is 
shown in Fig 5.  
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3.4 Between-Eye Mirror Symmetry of VAVFL 
The two components of the symmetry index for the FF135 and for the C30-2T are shown in 
Online Resource Videos 1, 2 and 3; at each stage of the modelled VAVFL in Figs 2 to 4; and 
for each measured field of those exposed to vigabatrin in Fig 6.  
 
3.5 Demographics of VAVFL  
The difference in the proportion with VAVFL by gender, 39 out of 44 males and 56 out of 63 
females, was not statistically significant.  
 
The mean age, at the time of perimetry, of those with VAVFL, 41.6 years (SD 14.4), was also 
similar to that of those exposed to vigabatrin but with normal fields, mean 37.9 years (SD 
7.9).  
 
Those with VAVFL manifested a greater cumulative dose (mean 7.94kg; SD 4.45; range 1.1 
to 20.7) and a longer duration of therapy (8.86 years; SD 3.51; range 0.66 to 16.05) at the 
time of perimetry than those without field loss (mean 3.36kg; SD 4.77; range 0.11 to 16.14;  
and mean 3.62 years; SD 3.94; range 0.33 to 11.83; respectively). The difference between 
means (Student’s t-test for two independent samples) were 4.58 kg (95% CI 1.71-7.45; 
p<0.001) and 5.25 years (95% CI 2.98-7.53; p<0.001), respectively.  
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There was no evidence of a relationship between the stage of the VAVFL and the extent of 
the exposure to vigabatrin at the time of perimetry. The median exposures at the time of 
perimetry which resulted in Stage One loss were 7.7kg cumulative dose (IQR 4.8, 12.1; range 
1.5-13.3) and 9.4 years (IQR 6.2, 12.1; range 2.4-16.1) and which resulted in Stage 6 loss 
were 6.7kg cumulative dose (IQR 4.4, 10.6; range 2.8-19.0) and 7.7 years (IQR 5.3, 10.6; 
range 3.1-13.0).    
 
There was also no association between the stage of VAVFL and either age, age at onset of 
epilepsy or age at onset of vigabatrin. 
 
4.0 Discussion 
 
The objective rolling median and symmetry index outcomes from the FF135 and the C30-2T 
confirm that vigabatrin is associated with symmetrical bilateral visual field loss. The VAVFL 
manifests over a range of severities that can be described in six stages. The field loss 
originates in the extreme temporal periphery and, as the severity increases, encroaches 
centripetally along all meridians towards fixation resulting in bi-nasal loss and relative 
temporal sparing until the end stage (Stage Six) which manifests as a concentric loss to 
within approximately 15° from fixation. The initial appearance in the central field (Stages 
Two and Three) is primarily inferior-nasally. VAVFL exhibits a high degree of between-eye 
mirror symmetry at each stage of loss. In contrast, the modelled field for the age-matched 
control individuals with no exposure to vigabatrin was entirely normal. 
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The apparent absence of initial loss superior-nasally within the central field is most likely 
attributable to the greater defect depth in this region required to achieve statistical 
significance. The latter, in turn, arises from the wider distribution of normal values arising 
from the between-individual variation in the position of the upper eyelid and from the 
increased variability in response associated with the steeper gradient of the superior visual 
field, compared to those inferior-nasally. 
 
The fundamental strengths of this retrospective study were the robust exclusion of individuals 
with retino-geniculo-cortical visual pathway abnormality; the inclusion of long-term 
exposures to vigabatrin (median 8.8 years; IQR 5.7 to 11.3; range 0.1 to 16.1) many of which 
are unparalleled in the literature; and the utilisation of the two novel objective techniques 
which have not previously been applied to perimetry.  These latter techniques enabled 
objective descriptions of the characteristics and between-eye mirror symmetry of VAVFL.  
 
The modelled field at all six stages is in agreement with that derived from cross-sectional 
retrospective evidence with kinetic perimetry [4]. The initial manifestation of the VAVFL in 
this latter model was defined as a ‘non-seen’ response to the Goldmann V4e isopter at 80° 
temporally and/ or at 40° nasally. This definition is entirely consistent with the location and 
depth of the loss described as Stage One in the current study: the absolute loss designated by 
the FF135 is equivalent to the Goldmann V4e stimulus. The increasing encroachment into the 
nasal field with relative sparing of the temporal field, during Stages Two to Five, is 
compatible with the model out to approximately 80° temporally, derived from cross-sectional 
evidence, using suprathreshold perimetry equivalent to the I4e isopter [30]. 
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The model was developed from the visual fields of adults. The reduction in amplitude of the 
30Hz flicker cone electroretinogram (ERG) in infants treated with vigabatrin for infantile 
spasms [31] is compatible with that for adults manifesting VAVFL [32]. Similarly, the 
topographical characteristics of the reduced peripapillary retinal nerve fibre layer thickness in 
children [33] is also compatible with that found in adults [34-38]. Those with vigabatrin-
associated 30Hz flicker cone ERG abnormality in infancy subsequently manifest VAVFL, 
and corresponding retinal nerve fibre layer thinning, in later childhood/ early adolescence 
[39]. There is no reason to suggest, therefore, that the vigabatrin toxicity manifested in 
infancy will result in a different appearance to the VAVFL when the latter measure is 
obtained in later life. 
 
The ophthalmological examinations were undertaken by any one of four ophthalmologists, 
depending upon the particular clinic, who were all unaware of the findings from their 
colleagues. All four were aware of the anti-epileptic drug history and, usually, of the visual 
field outcome. However, the modelling of the visual fields from those exposed to vigabatrin 
and from the control individuals was objective and independent of the outcome from the 
ophthalmological and neurological examinations.   
 
The most common bilateral finding by fundoscopy, through a dilated pupil, was either 
generalised or localised arteriolar narrowing which was noted at all stages of VAVFL. 
However, this finding was occasionally found in the presence of a normal field and, 
therefore, may well be associated with vigabatrin usage. Subtle bilateral retinal nerve fibre 
layer changes and optic nerve head pallor were noted from Stage 4 onwards. A variety of 
bilateral peripheral degenerative changes were also noted including hypo-pigmented/ white 
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spots and surface wrinkling.  However, there was considerable variation in the fundal 
appearance between-individuals within a given stage.  The various features are in agreement 
with those reported previously [3, 22, 40-41], were often subtle, and suggest that there is a 
wide spectrum of potential retinopathy associated with vigabatrin toxicity. There was no 
evidence of such findings in the individuals with no exposure to vigabatrin.  Twenty-nine 
individuals exposed to vigabatrin had undergone optical coherence tomography of the 
peripapillary retinal nerve fibre layer at the time of the examination. All three individuals 
who manifested a normal visual field exhibited a normal nerve fibre layer thickness.   Of the 
three individuals who had Stage 1 loss, two exhibited a normal thickness. An abnormally thin 
nerve fibre layer, characteristic of vigabatrin toxicity [34-38], was present from Stage 2 
onwards in 22 individuals. The one remaining individual manifested early Stage 2 VAVFL 
and a normal a normal nerve fibre layer thickness. 
 
The outcome of the current study and of the earlier models [4, 28] indicates that perimetry 
out to 60° eccentricity [42] is inadequate to detect Stage One and also possibly early Stage 
Two loss. Similarly, a worsening of 3dB from the baseline Mean Deviation (MD) index for 
the C30-2T, which was used as a primary outcome measure for the presence of VAVFL in 
the prospective Phase IV study [16], will not detect VAVFL until late in Stage Two or early 
in Stage Three. The MD is a summary measure of the central field and does not describe the 
spatial appearance of visual field loss: in the current study, the median MDs for the 
individuals exposed to vigabatrin and for the controls was -1.75dB and -1.23dB, respectively. 
 
It is clear from the staging of the VAVFL that perimetry should initially be undertaken with, 
in the case of the Humphrey Field Analyzer, the FF135. If the field is normal to the FF135 or 
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exhibits Stage One abnormality, the C30-2T is unnecessary. If the peripheral field exhibits 
Stage Two abnormality to the FF135, the C30-2T should also be undertaken to reveal the full 
depth of the loss since the magnitude of the Pattern Deviation value required for statistical 
significance at the extreme nasal locations within the central field can be less than the 8dB 
suprathreshold increment of the stimulus luminance of the FF135.  If the FF135 indicates 
both peripheral and central loss, i.e., Stage Three and worse, subsequent examinations need 
only be undertaken with the C30-2T. The Central 24-2 Threshold Test, alone, should only be 
used for Stage Six.  The characteristics of VAVFL are more prominent with the FASTPAC 
algorithm than with the SITA Standard or Fast algorithms which were designed to detect 
glaucomatous field loss. The peripheral manifestation of VAVFL is fortuitous since, in our 
experience, patients exposed to vigabatrin find suprathreshold perimetry considerably easier 
to perform than SAP. In cases where patients are unable to undertake SAP, assessment with 
the FF135, although collecting less information about relative loss, is acceptable.  
 
The staging of VAVFL was derived from cross-sectional evidence and does not imply 
progressive loss. Due to the potency of the potential toxicity, most individuals had been 
withdrawn from vigabatrin either immediately prior to the introduction into the care regime 
of the visual field examination or following confirmation of the VAVFL. As such, neither the 
probability of progression at each stage nor an estimate of the rate of progression can be 
determined. However, the presumption is that, given continued vigabatrin therapy, VAVFL 
will progress through the various stages. The lack of an association between the stage of loss, 
at detection, and either the duration or the cumulative dose of vigabatrin implies that the 
relationship between the extent of exposure and both the onset and the severity of VAVFL 
varies depending upon the individual susceptibility to vigabatrin. However, the time of 
detection is not the time to onset of the VAVFL. The rate of any subsequent progression, 
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therefore, remains unknown. A case of progressive loss during approximately 7.75 years of 
vigabatrin therapy and illustrated in terms of the Pattern Deviation probability map of the 
Central 24-2 Threshold Test and, subsequently, the C30-2T is shown in Fig 6. The outcome 
of the corresponding FF135 at the final visit is shown in Online Resource Fig 4. Progressive 
loss whilst on therapy has been shown over a mean follow-up of 10.7 years; the rate of 
reduction in the I4e isopter of kinetic perimetry increased with increase in cumulative dose 
[6]. An unpublished audit of the long-term follow-up, over a maximum of eight years, of 
individuals in the current study indicates that the VAVFL neither improves nor deteriorates 
following withdrawal of vigabatrin.  
 
The appearance of Stage One VAVFL should act as an alert signal for a re-evaluation of the 
management of the epilepsy. This may encompass either a change in anti-epileptic drug 
therapy or an increase in the frequency of neuro-ophthalmological monitoring.  However, the 
extreme peripheral stimulus locations of the FF135 are also influenced by the facial anatomy, 
particularly superiorly and inferior-nasally. The outcome of the examination at such 
locations, and those in the extreme temporal periphery, is also dependent upon the vigilance 
of the patient. Indeed, normal individuals do not necessarily produce statistically normal 
visual fields. The FF135 commences with the examination of the central field. Once 
completed, the examination pauses for removal of the trial lenses prior to the examination of 
the peripheral field. Instructions to the patient, during this pause, to the effect that the stimuli 
are about to appear in the (extreme) periphery, together with an exhortation to keep the eye 
‘wide open’, generally leads to a ‘seen’ response, in the normal eye, at these extreme 
locations. However, individuals with epilepsy frequently exhibit greater within-examination 
variability than normal individuals, which can lead to the impression of visual field loss, and 
approximately 30% of individuals with epilepsy are unable to undertake perimetry of any 
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type [15, 32]. The clinical skill lies in the identification of actual visual field loss, 
characteristic of the given lesion, from apparent visual field loss due to increased variability 
and/ or an inability to understand the requirements of the test. In addition, VAVFL frequently 
co-exists with that arising from an intra-cranial lesion. 
 
Fourteen individuals exhibited Stage Six VAVFL.  Great care was taken to exclude 
individuals manifesting visual field loss of suspected psychogenic origin from the case series 
[44]. Three of these 14 individuals had undergone optical coherence tomography and 
exhibited severe thinning of the retinal nerve fibre layer. All 14 individuals exhibited 
profoundly impaired mobility and reported symptoms explainable by their VAVFL, the most 
common of which was bumping into individuals in crowded locations. However, some 
individuals with Stage 5 VAVFL also reported a negative impact on their activities of daily 
living. 
 
The study utilised a retrospective cross-sectional design. However, the objective derivation of 
field loss based upon signal-to-noise theory, further supported by the stringent 
ophthalmological and neurological inclusion criteria, uniquely facilitated a retrospective 
design and largely obviated the need for a prospective study referenced to a pre-treatment 
baseline.  
 
The variable and lengthy time to onset of VAVFL together with the opportunity to study a 
wide range of long-term exposures, further highlights the pragmatism of this retrospective 
study compared to a prospective study.  Nevertheless, prospective longitudinal studies over 
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the long-term would unequivocally rule out the presence of abnormality at baseline and 
would also determine the evolution of the field loss.  
 
5.0 Conclusions 
The appearance of VAVFL has received little attention. This absence of knowledge hinders not 
only the recognition of the onset, and of any progression, of the field loss but also the 
differentiation from other (concomitant) types of loss. The staging of the VAVFL derived from a 
regulatory approved perimetric protocol, and reported here, should assist clinicians and patients, 
alike, in the risk:benefit analysis of vigabatrin for the treatment of epilepsy.  
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Figure Captions 
 
Fig 1 The number of individuals by anti-epileptic drug exposure, type of perimetry and visual 
field outcome. Equivocal indicates a normal outcome to the Central 30-2 Threshold Test; 
however, in the absence of the Full Field 135 Point Screening Test with the three zone age-
corrected strategy, an evaluation for VAVFL was not possible. VAVFL indicates vigabatrin-
associated visual field loss 
 
 
Fig 2 Stages One and Two of vigabatrin-associated visual field loss for the Full Field 135 
Point Screening Test with the three zone age-corrected strategy and for the Central 30-2 
Threshold Test  
For the Full Field 135 Point Screening Test,  represents a ‘seen’ response to the initial 
(dimmest) stimulus luminance;  represents a ‘non-seen’ response to the initial (dimmest) 
stimulus luminance but a ‘seen’ response to the maximum (brightest) stimulus luminance; 
represents a ‘non-seen’ response to the maximum (brightest) stimulus luminance 
For the Central 30-2 Threshold Test, MD indicates Mean Deviation, PSD indicates Pattern 
Standard Deviation and SI indicates Symmetry Index. The symbols , ,  and  indicate the 
probability of the difference between the measured value of sensitivity and the corresponding 
age-corrected normal value, after the general height adjustment, lying within the statistically 
normal range at p<5%, p<2%, p<1% and p<0.5%, respectively 
 
 
Fig 3 Stages Three and Four of vigabatrin-associated visual field loss for the Full Field 135 
Point Screening Test with the three zone age-corrected strategy and for the Central 30-2 
Threshold Test.  
For the Full Field 135 Point Screening Test,  represents a ‘seen’ response to the initial 
(dimmest) stimulus luminance;  represents a ‘non-seen’ response to the initial (dimmest) 
stimulus luminance but a ‘seen’ response to the maximum (brightest) stimulus luminance; 
represents a ‘non-seen’ response to the maximum (brightest) stimulus luminance 
For the Central 30-2 Threshold Test, MD indicates Mean Deviation, PSD indicates Pattern 
Standard Deviation and SI indicates Symmetry Index. The symbols , ,  and  indicate the 
probability of the difference between the measured value of sensitivity and the corresponding 
age-corrected normal value, after the general height adjustment, lying within the statistically 
normal range at p<5%, p<2%, p<1% and p<0.5%, respectively 
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Fig 4 Stages Five and Six of vigabatrin-associated visual field loss for the Full Field 135 
Point Screening Test with the three zone age-corrected strategy and for the Central 30-2 
Threshold Test.  
For the Full Field 135 Point Screening Test,  represents a ‘seen’ response to the initial 
(dimmest) stimulus luminance;  represents a ‘non-seen’ response to the initial (dimmest) 
stimulus luminance but a ‘seen’ response to the maximum (brightest) stimulus luminance; 
represents a ‘non-seen’ response to the maximum (brightest) stimulus luminance 
For the Central 30-2 Threshold Test, MD indicates Mean Deviation, PSD indicates Pattern 
Standard Deviation and SI indicates Symmetry Index. The symbols , ,  and  indicate the 
probability of the difference between the measured value of sensitivity and the corresponding 
age-corrected normal value, after the general height adjustment, lying within the statistically 
normal range at p<5%, p<2%, p<1% and p<0.5%, respectively 
 
 
Fig 5 The Mean Deviation and Pattern Standard Deviation as a function of the ranked 
outcome of the Central 30-2 Threshold Test for each eye of the 99 individuals. The circles 
represent the Mean Deviation and the squares the Pattern Standard Deviation. The black 
symbols represent the outcome from the right eye and the open symbols that from the left eye 
 
 
Fig 6. The two components of the symmetry index. The coloured area comprises the data 
points from one million randomly generated pairs of fields, each of which possesses differing 
within- and between-eye levels of field loss and represents the likelihood of the symmetry 
outcome occurring due to chance at p>0.01. The black circles represent individuals exposed 
to vigabatrin, the vast majority of which lie above the shaded area indicating a high level of 
symmetry. Note the circles in the bottom left hand corner indicate an absence of symmetry 
since the fields are normal and those in the top right corner indicate a high degree of 
symmetry since the fields exhibit advanced loss. The scale on the right hand ordinate 
indicates the level of probability attributable to a random occurrence of symmetry: any circle 
lying within the white region exhibits a p≤0.01 of symmetry occurring due to chance 
 
 
Fig 7 A case of progressive VAVFL within the central field of each eye, illustrated in terms 
of the Pattern Deviation probability map. The visual fields up to 82 months from onset of 
therapy were obtained using the Central 24-2 Threshold Test and subsequently with the 
Central 30-2 Threshold Test. Vigabatrin was withdrawn after 93 months of therapy. The 
patient remained asymptomatic. MD indicates Mean Deviation and PSD indicates Pattern 
Standard Deviation. The outcome of the Full Field 135 Point Screening Test at 101 months is 
given in Online Resource Fig 5 
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Abstract 
Background The morphology and between-eye symmetry of the visual field loss associated with 
the anti-epileptic drug vigabatrin (VAVFL) has received little attention. 
Objective To model the appearance, and ensuing staging, of VAVFL, derived with the European 
Medicines Agency approved perimetric protocol. 
Methods A retrospective, cross-sectional, observational design identified 123 adults who had 
received vigabatrin for refractory seizures and who had no evidence of co-existing retino-
geniculo-cortical visual pathway abnormality. Thirty-eight adults with refractory seizures and 
identical inclusion criteria, but no exposure to vigabatrin, acted as controls. For each group, the 
median outcome at each stimulus location in each eye (of absolute loss, relative loss or Pattern 
Deviation probability level, as appropriate) was derived for each successive ten pairs of fields, 
ranked for severity. Between-eye symmetry was quantified by an index which accounted for 
severity of loss and which was referenced to the likelihood of the occurrence of symmetry due to 
chance.  
Results The modelled VAVFL was bilateral and highly symmetrical and was described by six 
stages which were all independent of the extent of vigabatrin exposure. The loss originated in the 
extreme temporal periphery and encroached centripetally along all meridians towards fixation. 
The initial appearance within the central field (Stage Two) occurred inferior-nasally. Subsequent 
stages exhibited increasing loss which was greater nasally than temporally. Stage Six described 
concentric loss extending to approximately 15° eccentricity from fixation.  
Conclusion The model exhibited a consistent pattern of VAVFL. The staging of the loss could 
assist the risk:benefit analysis of vigabatrin for the treatment of epilepsy. 
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Key Points 
 
In this study of 123 individuals treated with vigabatrin as adjunct therapy for refractory focal 
seizures and without evidence of other retino-geniculo-cortical visual pathway abnormality, 
objective modelling, based upon convolution theory used in signal-to-noise processing, 
identified a consistent pattern of bilateral symmetrical visual field loss obtained using a 
regulatory approved perimetric protocol. No modelled field loss was present for the 38 
individuals with identical inclusion criteria but no exposure to vigabatrin.    
Six stages of modelled vigabatrin-associated field loss (VAVFL) were evident. Originating in 
the extreme temporal periphery, the field loss encroached, with increasing severity, 
centripetally along all meridians towards fixation with greater nasal than temporal loss. Stage 
Six manifested as concentric loss to within approximately 15° from fixation.  
The between-eye mirror symmetry of the VAVFL at all stages, quantified by a novel index, 
which accounted for the severity of loss, was not attributable to chance (p≤0.01). 
The use of either the Central 30-2 or the Central 24-2 Threshold Tests, alone, will not identify 
VAVFL until late Stage Two and late stage Three, respectively.  
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1.0 Introduction 
The anti-epileptic drug vigabatrin has long been associated with visual field loss (VAVFL) [1-2] 
which manifests as a bilateral concentric peripheral defect over a continuum of severity and 
which, generally, also involves the central field to varying extents [3-4]. The field loss is 
considered to be slowly progressive [5-7] irreversible but non-progressive on withdrawal from 
vigabatrin [8-9] and asymptomatic until severe loss is present [3, 10-12]. The modelled 
prevalence of VAVFL in adults increases rapidly after the first two years (2kg cumulative dose) 
of exposure [13-14]  and can reach 75-80% after approximately six years (5kg cumulative dose) 
[14]. Vigabatrin is now available generically.   
 
The association between vigabatrin and ocular toxicity is currently being re-evaluated [15-17] on 
the basis that the attribution of the toxicity emanates from retrospective studies which do not 
include a pre-treatment baseline evaluation. The lack of evidence for the toxicity in the two 
prospective studies alongside the finding that approximately 25% of individuals suitable for 
vigabatrin exhibited clinically significant pre-existing reduced visual acuity and/ or visual field 
loss and/ or peripapillary retinal nerve fibre layer thinning, has led to the suggestion that 
abnormalities of the afferent system are a co-morbidity of severe refractory epilepsy and are 
unrelated to vigabatrin [15-16]. However, the limited exposures to vigabatrin and the poor 
retention of individuals, within these two studies [15-16], together with inappropriate visual field 
methodologies and analyses, have not facilitated detection of the toxicity.   
 
Surprisingly, there has been little emphasis on the areal and depth characteristics, the between 
eye-symmetry, and the staging, of VAVFL.  Such information is essential not only to identify the 
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onset and the progression of the VAVFL but also to differentiate it from other types of 
(concomitant) field loss.  
 
The areal extent and the depth of any type of visual field loss is highly dependent upon the 
perimetric technique used for the examination. VAVFL has been investigated by a variety of 
methods [7, 10-11, 16, 18-23] but the characteristics of the field loss by each technique have 
received little attention. Unfortunately, due to the peripheral nature of the field loss, there is no 
one ideal technique, across the current range of commercially available perimeters, for the 
assessment of VAVFL. The most pragmatic approach is that approved by the European 
Medicines Agency (EMA) [23] namely, Three Zone (two luminance level) suprathreshold 
perimetry, referenced to the age-corrected threshold, of the peripheral field out to a maximum 
temporal extent of 90° eccentricity and standard automated perimetry of the central field (SAP).  
 
Given the on-going re-evaluation of the association between vigabatrin and visual field loss and 
the wider availability of the drug, a description of the morphology and staging of the VAVFL 
resulting from the EMA approved protocol, and derived from individuals with long-term 
exposures to vigabatrin, would be of benefit to clinicians and to patients, alike. If such a 
description was based upon a technique which reduced the signal-to-noise ratio and was derived 
from individuals with no evidence of retino-geniculo-cortical visual pathway abnormality, except 
that of potential vigabatrin toxicity, the characteristics of the field loss attributable to vigabatrin 
would become manifest from backgrounds of any unexpected field loss and of any increased 
variability associated with the response by the patient. Such an approach would also enable the 
use of the visual fields from individuals with long-term exposures to vigabatrin but with no pre-
treatment baseline.  
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The aim of the study, therefore, was threefold: to model the morphology of VAVFL obtained 
with the EMA approved perimetric protocol and resulting from long-term vigabatrin therapy; to 
quantify any between-eye symmetry; and to describe the ensuing staging of the field loss. 
 
2.0 Methods 
 
2.1 Case series 
A retrospective case series comprising 161 adults with refractory complex partial (focal) seizures 
was compiled from those presenting to the Alan Richens Unit of the Welsh Epilepsy Centre, 
University Hospital of Wales, Cardiff, UK, and to associated clinics. All individuals had 
undergone part or all of the EMA approved protocol with the Humphrey Field Analyzer 750 
(Carl Zeiss, Meditec, Dublin, CA) namely, the Full Field 135 Point Test with the three zone age-
corrected strategy (FF135) and the Central 30-2 Threshold Test (C30-2T) with the FASTPAC 
strategy. None exhibited ocular or intra-cranial conditions resulting in, or likely to cause, visual 
field loss, as determined by ophthalmological and neurological examination including whole-
brain magnetic resonance imaging. Further exclusion criteria comprised the presence of 
structural and/or functional ocular abnormalities likely to impede or confound the outcome of 
perimetry and which are described elsewhere [24]. There was no conscious selection bias. 
Individuals were included on the basis of sequential retrieval of cases which met the inclusion/ 
exclusion criteria.  
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2.2 Vigabatrin exposure  
Of the 161 individuals (Fig 1, top row), 123 had been exposed to vigabatrin as add-on therapy. 
The remaining 38 individuals had received a variety of other antiepileptic drugs and were included 
as age-matched controls.  
 
2.3 Perimetry 
Sixty-three of the 123 individuals exposed to vigabatrin and all 38 of those exposed to other 
antiepileptic drugs had undergone the complete EMA approved protocol (Fig 1, second row). Of 
the remaining 60 individuals exposed to vigabatrin, 24 had undergone the FF135, only, and 36 
had undergone the C30-2T, only (Fig 1, second row) as ordered by the treating neurologist on 
clinical grounds. Thus, 87 of the 123 individuals exposed to vigabatrin had undertaken the 
FF135 and 99 individuals had undertaken the C30-2T.  
 
The visual fields from the first occasion, after the first visit, at which reliable perimetric 
outcomes had been achieved were used for the individuals in each of the two groups. The 
reliability criteria comprised ≤20% incorrect responses to the fixation loss catch trials and ≤15% 
incorrect responses to the false-positive catch trials. A criterion of ≤30% incorrect responses was 
used for the false-negative catch trials although this was widened with increasing severity of the 
field loss [25]. All individuals had been seizure free for a minimum of 24 hours prior to the 
visual field examination. 
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2.4 Morphology of visual field loss 
The Single Field Printouts of the FF135 and of the C30-2T were exported to a personal computer 
via a Humphrey Field Analyzer 820 and saved in Tagged Image File Format. The outputs from 
each eye for both types of perimetry were then read by custom Naïve Bayesian character 
recognition software [26].  
 
The fields were separately sorted for each group, and for each type of perimetry, as right and left 
eye pairs, and ranked from the least to the most affected field. The severity of the given pair of 
fields was defined as the sum, across the two eyes, of the number of defects, weighted to account 
for relative or absolute loss, respectively, derived by the FF135 and/ or for the probability level 
of the Pattern Deviation probability map derived by the C30-2T. In the case of those undergoing 
both tests, the outcome from the C30-2T was more heavily weighted.  
 
The median outcome for each group at each stimulus location in each eye for each type of 
perimetry was then separately calculated for each successive ten pairs of fields, ranked for 
severity. Such an approach was based upon convolution theory used in signal processing [27].  
The procedure resulted in 54 pairs of modelled fields from the 63 individuals exposed to 
vigabatrin who had undergone the combined EMA protocol; 78 pairs for the FF135 and 90 for 
the C30-2T.  Twenty-nine pairs of modelled fields resulted from the 38 individuals with no 
vigabatrin exposure.  The outcomes for the right and left eyes, separately, were then displayed in 
terms of Audio Video Interleaved (AVI) movies. 
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2.5 Between-eye mirror symmetry of visual field loss 
The between-eye mirror symmetry of the field was expressed in terms of a single index which 
comprised two components, each of which was a fraction. The index accounted for the severity 
of loss and was compared to the likelihood of obtaining symmetrical field loss due to chance. 
The numerator and denominator of the first component constituted of, respectively, the number 
of mirror image stimulus locations between the two eyes which exhibited either relative or 
absolute loss for the FF135, or abnormality at p≤0.02 by Pattern Deviation probability analysis 
for the C30-2T, and the total number of locations exhibiting abnormality across the two eyes. 
The numerator and denominator of the second component comprised, respectively, the total 
number of locations exhibiting abnormality across the two eyes and the total number of stimulus 
locations across the two eyes.  The index was compared to that obtained from the simulation of 
one million randomly generated pairs of abnormal fields which manifested varying locations, 
areas and depths of field loss both within- and between-eyes. The concept was such that 
symmetry would become apparent when compared to a series of pairs of fields with varying 
characteristics of asymmetric field loss.  
 
The symmetry index was separately calculated for each pair of peripheral, and each pair of 
central fields, for the modelled fields and for the measured fields.  
 
2.6 Staging of the measured fields for those exposed to vigabatrin 
The staging of the VAVFL was derived from the modelled fields. The stages were empirically 
selected on the basis of clinically meaningful intervals of peripheral field loss and, subsequently, 
of central field loss. These intervals, in turn, were based upon the magnitude of the between-
examination physiological variability in the differential light sensitivity as a function of severity 
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of loss [28-29].   The derivation ensured continuity across stages. The staging of the modelled 
peripheral fields was undertaken masked to that of the modelled central fields. The outcome of 
the staging of the central and peripheral fields, with respect to one another, was then validated 
based upon the outcome of the model from the individuals who had undergone the combined 
protocol. The staging was then applied to each of the 87 pairs of measured fields from the FF135 
and to each of the 99 measured fields from the C30-2T. 
 
3.0 Results 
 
3.1 Demographic characteristics of the case series 
Of the 123 individuals exposed to vigabatrin, 50 were male and 73 female. Thirty-five were 
receiving vigabatrin at the time of perimetry. Of the 38 age-matched controls, 17 were male 
and 21 female. The mean ages of the two groups, at the time of perimetry, were 40.8 years 
(SD 13.6) and 38.5 years (SD 10.0), respectively. 
 
3.2 Morphology of VAVFL 
The rolling medians of the 78 pairs of modelled fields for the FF135 from those exposed to 
vigabatrin; of the 90 pairs for the C30-2T; and of the 54 pairs for the combined EMA 
protocol are given in video format in Online Resource Figs 1, 2 and 3, respectively.  
 
The rolling medians of the 29 pairs of modelled fields for the combined EMA protocol from 
those with no exposure to vigabatrin are given in video format in Online Resource Fig 4.  The 
modelled fields showed was no evidence of visual field loss.  
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3.3 Staging of VAVFL 
The staging of the FF135 and of the C30-2T modelled fields for those exposed to vigabatrin 
is shown in Figs 2 to 4.  
 
Sixteen of the 36 individuals exposed to vigabatrin, who had undergone the C30-2T, only, 
manifested a normal measured central field (Fig 1 third row). These 16 fields were included 
in the model, but, in the absence of a peripheral field assessment, the individuals could not be 
categorised as to the potential outcome of the toxicity and were considered as equivocal.   
 
Of the remaining 107 individuals exposed to vigabatrin (Fig 1, fourth row), 12 exhibited 
normal measured fields and 95 field loss which conformed to the modelled fields and which 
was therefore designated as VAVFL.  
 
The frequency, by stage, of VAVFL is shown in Fig 1 (bottom row). Fourteen of the 95 
individuals with VAVFL exhibited Stage One VAVFL, 21 Stage Two, 14 Stage Three, 22 
Stage Four, 10 Stage Five and 14 Stage Six.  
 
The relationship between the stage of loss and the summary measures of the visual field, 
Mean Deviation (MD) and Pattern Standard Deviation, for the C30-2T measured fields is 
shown in Fig 5.  
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3.4 Between-Eye Mirror Symmetry of VAVFL 
The two components of the symmetry index for the FF135 and for the C30-2T are shown in 
Online Resource Videos 1, 2 and 3; at each stage of the modelled VAVFL in Figs 2 to 4; and 
for each measured field of those exposed to vigabatrin in Fig 6.  
 
3.5 Demographics of VAVFL  
The difference in the proportion with VAVFL by gender, 39 out of 44 males and 56 out of 63 
females, was not statistically significant.  
 
The mean age, at the time of perimetry, of those with VAVFL, 41.6 years (SD 14.4), was also 
similar to that of those exposed to vigabatrin but with normal fields, mean 37.9 years (SD 
7.9).  
 
Those with VAVFL manifested a greater cumulative dose (mean 7.94kg; SD 4.45; range 1.1 
to 20.7) and a longer duration of therapy (8.86 years; SD 3.51; range 0.66 to 16.05) at the 
time of perimetry than those without field loss (mean 3.36kg; SD 4.77; range 0.11 to 16.14;  
and mean 3.62 years; SD 3.94; range 0.33 to 11.83; respectively). The difference between 
means (Student’s t-test for two independent samples) were 4.58 kg (95% CI 1.71-7.45; 
p<0.001) and 5.25 years (95% CI 2.98-7.53; p<0.001), respectively.  
 
There was no evidence of a relationship between the stage of the VAVFL and the extent of 
the exposure to vigabatrin at the time of perimetry. The median exposures at the time of 
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perimetry which resulted in Stage One loss were 7.7kg cumulative dose (IQR 4.8, 12.1; range 
1.5-13.3) and 9.4 years (IQR 6.2, 12.1; range 2.4-16.1) and which resulted in Stage 6 loss 
were 6.7kg cumulative dose (IQR 4.4, 10.6; range 2.8-19.0) and 7.7 years (IQR 5.3, 10.6; 
range 3.1-13.0).    
 
There was also no association between the stage of VAVFL and either age, age at onset of 
epilepsy or age at onset of vigabatrin. 
 
4.0 Discussion 
 
The objective rolling median and symmetry index outcomes from the FF135 and the C30-2T 
confirm that vigabatrin is associated with symmetrical bilateral visual field loss. The VAVFL 
manifests over a range of severities that can be described in six stages. The field loss 
originates in the extreme temporal periphery and, as the severity increases, encroaches 
centripetally along all meridians towards fixation resulting in bi-nasal loss and relative 
temporal sparing until the end stage (Stage Six) which manifests as a concentric loss to 
within approximately 15° from fixation. The initial appearance in the central field (Stages 
Two and Three) is primarily inferior-nasally. VAVFL exhibits a high degree of between-eye 
mirror symmetry at each stage of loss. In contrast, the modelled field for the age-matched 
control individuals with no exposure to vigabatrin was entirely normal. 
 
The apparent absence of initial loss superior-nasally within the central field is most likely 
attributable to the greater defect depth in this region required to achieve statistical 
significance. The latter, in turn, arises from the wider distribution of normal values arising 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                        Staging of vigabatrin-associated visual field loss 
14 
 
from the between-individual variation in the position of the upper eyelid and from the 
increased variability in response associated with the steeper gradient of the superior visual 
field, compared to those inferior-nasally. 
 
The fundamental strengths of this retrospective study were the robust exclusion of individuals 
with retino-geniculo-cortical visual pathway abnormality; the inclusion of long-term 
exposures to vigabatrin (median 8.8 years; IQR 5.7 to 11.3; range 0.1 to 16.1) many of which 
are unparalleled in the literature; and the utilisation of the two novel objective techniques 
which have not previously been applied to perimetry.  These latter techniques enabled 
objective descriptions of the characteristics and between-eye mirror symmetry of VAVFL.  
 
The modelled field at all six stages is in agreement with that derived from cross-sectional 
retrospective evidence with kinetic perimetry [4]. The initial manifestation of the VAVFL in 
this latter model was defined as a ‘non-seen’ response to the Goldmann V4e isopter at 80° 
temporally and/ or at 40° nasally. This definition is entirely consistent with the location and 
depth of the loss described as Stage One in the current study: the absolute loss designated by 
the FF135 is equivalent to the Goldmann V4e stimulus. The increasing encroachment into the 
nasal field with relative sparing of the temporal field, during Stages Two to Five, is 
compatible with the model out to approximately 80° temporally, derived from cross-sectional 
evidence, using suprathreshold perimetry equivalent to the I4e isopter [30]. 
 
The model was developed from the visual fields of adults. The reduction in amplitude of the 
30Hz flicker cone electroretinogram (ERG) in infants treated with vigabatrin for infantile 
spasms [31] is compatible with that for adults manifesting VAVFL [32]. Similarly, the 
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topographical characteristics of the reduced peripapillary retinal nerve fibre layer thickness in 
children [33] is also compatible with that found in adults [34-38]. Those with vigabatrin-
associated 30Hz flicker cone ERG abnormality in infancy subsequently manifest VAVFL, 
and corresponding retinal nerve fibre layer thinning, in later childhood/ early adolescence 
[39]. There is no reason to suggest, therefore, that the vigabatrin toxicity manifested in 
infancy will result in a different appearance to the VAVFL when the latter measure is 
obtained in later life. 
 
The ophthalmological examinations were undertaken by any one of four ophthalmologists, 
depending upon the particular clinic, who were all unaware of the findings from their 
colleagues. All four were aware of the anti-epileptic drug history and, usually, of the visual 
field outcome. However, the modelling of the visual fields from those exposed to vigabatrin 
and from the control individuals was objective and independent of the outcome from the 
ophthalmological and neurological examinations.   
 
The most common bilateral finding by fundoscopy, through a dilated pupil, was either 
generalised or localised arteriolar narrowing which was noted at all stages of VAVFL. 
However, this finding was occasionally found in the presence of a normal field and, 
therefore, may well be associated with vigabatrin usage. Subtle bilateral retinal nerve fibre 
layer changes and optic nerve head pallor were noted from Stage 4 onwards. A variety of 
bilateral peripheral degenerative changes were also noted including hypopigmented/ white 
spots and surface wrinkling.  However, there was considerable variation in the fundal 
appearance between-individuals within a given stage.  The various features are in agreement 
with those reported previously [3, 22, 40-41], were often subtle, and suggest that there is a 
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wide spectrum of potential retinopathy associated with vigabatrin toxicity. There was no 
evidence of such findings in the individuals with no exposure to vigabatrin.  Twenty-nine 
individuals exposed to vigabatrin had undergone optical coherence tomography of the 
peripapillary retinal nerve fibre layer at the time of the examination. All three individuals 
who manifested a normal visual field exhibited a normal nerve fibre layer thickness.   Of the 
three individuals who had Stage 1 loss, two exhibited a normal thickness. An abnormally thin 
nerve fibre layer, characteristic of vigabatrin toxicity [34-38], was present from Stage 2 
onwards in 22 individuals. The one remaining individual manifested early Stage 2 VAVFL 
and a normal a normal nerve fibre layer thickness. 
 
The outcome of the current study and of the earlier models [4, 28] indicates that perimetry 
out to 60° eccentricity [42] is inadequate to detect Stage One and also possibly early Stage 
Two loss. Similarly, a worsening of 3dB from the baseline Mean Deviation (MD) index for 
the C30-2T, which was used as a primary outcome measure for the presence of VAVFL in 
the prospective Phase IV study [16], will not detect VAVFL until late in Stage Two or early 
in Stage Three. The MD is a summary measure of the central field and does not describe the 
spatial appearance of visual field loss: in the current study, the median MDs for the 
individuals exposed to vigabatrin and for the controls was -1.75dB and -1.23dB, respectively. 
 
It is clear from the staging of the VAVFL that perimetry should initially be undertaken with, 
in the case of the Humphrey Field Analyzer, the FF135. If the field is normal to the FF135 or 
exhibits Stage One abnormality, the C30-2T is unnecessary. If the peripheral field exhibits 
Stage Two abnormality to the FF135, the C30-2T should also be undertaken to reveal the full 
depth of the loss since the magnitude of the Pattern Deviation value required for statistical 
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significance at the extreme nasal locations within the central field can be less than the 8dB 
suprathreshold increment of the stimulus luminance of the FF135.  If the FF135 indicates 
both peripheral and central loss, i.e., Stage Three and worse, subsequent examinations need 
only be undertaken with the C30-2T. The Central 24-2 Threshold Test, alone, should only be 
used for Stage Six.  The characteristics of VAVFL are more prominent with the FASTPAC 
algorithm than with the SITA Standard or Fast algorithms which were designed to detect 
glaucomatous field loss. The peripheral manifestation of VAVFL is fortuitous since, in our 
experience, patients exposed to vigabatrin find suprathreshold perimetry considerably easier 
to perform than SAP. In cases where patients are unable to undertake SAP, assessment with 
the FF135, although collecting less information about relative loss, is acceptable.  
 
The staging of VAVFL was derived from cross-sectional evidence and does not imply 
progressive loss. Due to the potency of the potential toxicity, most individuals had been 
withdrawn from vigabatrin either immediately prior to the introduction into the care regime 
of the visual field examination or following confirmation of the VAVFL. As such, neither the 
probability of progression at each stage nor an estimate of the rate of progression can be 
determined. However, the presumption is that, given continued vigabatrin therapy, VAVFL 
will progress through the various stages. The lack of an association between the stage of loss, 
at detection, and either the duration or the cumulative dose of vigabatrin implies that the 
relationship between the extent of exposure and both the onset and the severity of VAVFL 
varies depending upon the individual susceptibility to vigabatrin. However, the time of 
detection is not the time to onset of the VAVFL. The rate of any subsequent progression, 
therefore, remains unknown. A case of progressive loss during approximately 7.75 years of 
vigabatrin therapy and illustrated in terms of the Pattern Deviation probability map of the 
Central 24-2 Threshold Test and, subsequently, the C30-2T is shown in Fig 6. The outcome 
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of the corresponding FF135 at the final visit is shown in Online Resource Fig 4. Progressive 
loss whilst on therapy has been shown over a mean follow-up of 10.7 years; the rate of 
reduction in the I4e isopter of kinetic perimetry increased with increase in cumulative dose 
[6]. An unpublished audit of the long-term follow-up, over a maximum of eight years, of 
individuals in the current study indicates that the VAVFL neither improves nor deteriorates 
following withdrawal of vigabatrin.  
 
The appearance of Stage One VAVFL should act as an alert signal for a re-evaluation of the 
management of the epilepsy. This may encompass either a change in anti-epileptic drug 
therapy or an increase in the frequency of neuro-ophthalmological monitoring.  However, the 
extreme peripheral stimulus locations of the FF135 are also influenced by the facial anatomy, 
particularly superiorly and inferior-nasally. The outcome of the examination at such 
locations, and those in the extreme temporal periphery, is also dependent upon the vigilance 
of the patient. Indeed, normal individuals do not necessarily produce statistically normal 
visual fields. The FF135 commences with the examination of the central field. Once 
completed, the examination pauses for removal of the trial lenses prior to the examination of 
the peripheral field. Instructions to the patient, during this pause, to the effect that the stimuli 
are about to appear in the (extreme) periphery, together with an exhortation to keep the eye 
‘wide open’, generally leads to a ‘seen’ response, in the normal eye, at these extreme 
locations. However, individuals with epilepsy frequently exhibit greater within-examination 
variability than normal individuals, which can lead to the impression of visual field loss, and 
approximately 30% of individuals with epilepsy are unable to undertake perimetry of any 
type [15,32]. The clinical skill lies in the identification of actual visual field loss, 
characteristic of the given lesion, from apparent visual field loss due to increased variability 
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and/ or an inability to understand the requirements of the test. In addition, VAVFL frequently 
co-exists with that arising from an intra-cranial lesion. 
 
Fourteen individuals exhibited Stage Six VAVFL.  Great care was taken to exclude individuals 
manifesting visual field loss of suspected psychogenic origin from the case series [43]. Three 
of these 14 individuals had undergone optical coherence tomography and exhibited severe 
thinning of the retinal nerve fibre layer. All 14 individuals exhibited profoundly impaired 
mobility and reported symptoms explainable by their VAVFL, the most common of which was 
bumping into individuals in crowded locations. However, some individuals with Stage 5 
VAVFL also reported a negative impact on their activities of daily living. 
 
The study utilised a retrospective cross-sectional design. However, the objective derivation of 
field loss based upon signal-to-noise theory, further supported by the stringent 
ophthalmological and neurological inclusion criteria, uniquely facilitated a retrospective 
design and largely obviated the need for a prospective study referenced to a pre-treatment 
baseline.  
 
The variable and lengthy time to onset of VAVFL together with the opportunity to study a 
wide range of long-term exposures, further highlights the pragmatism of this retrospective 
study compared to a prospective study.  Nevertheless, prospective longitudinal studies over 
the long-term would unequivocally rule out the presence of abnormality at baseline and 
would also determine the evolution of the field loss.  
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5.0 Conclusions 
The appearance of VAVFL has received little attention. This absence of knowledge hinders not 
only the recognition of the onset, and of any progression, of the field loss but also the 
differentiation from other (concomitant) types of loss. The staging of the VAVFL derived from a 
regulatory approved perimetric protocol, and reported here, should assist clinicians and patients, 
alike, in the risk:benefit analysis of vigabatrin for the treatment of epilepsy.  
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Figure Captions 
 
Fig 1 The number of individuals by anti-epileptic drug exposure, type of perimetry and visual 
field outcome. Equivocal indicates a normal outcome to the Central 30-2 Threshold Test; 
however, in the absence of the Full Field 135 Point Screening Test with the three zone age-
corrected strategy, an evaluation for VAVFL was not possible. VAVFL indicates vigabatrin-
associated visual field loss 
 
 
Fig 2 Stages One and Two of vigabatrin-associated visual field loss for the Full Field 135 
Point Screening Test with the three zone age-corrected strategy and for the Central 30-2 
Threshold Test  
For the Full Field 135 Point Screening Test,  represents a ‘seen’ response to the initial 
(dimmest) stimulus luminance;  represents a ‘non-seen’ response to the initial (dimmest) 
stimulus luminance but a ‘seen’ response to the maximum (brightest) stimulus luminance; 
represents a ‘non-seen’ response to the maximum (brightest) stimulus luminance 
For the Central 30-2 Threshold Test, MD indicates Mean Deviation, PSD indicates Pattern 
Standard Deviation and SI indicates Symmetry Index. The symbols , ,  and  indicate the 
probability of the difference between the measured value of sensitivity and the corresponding 
age-corrected normal value, after the general height adjustment, lying within the statistically 
normal range at p<5%, p<2%, p<1% and p<0.5%, respectively 
 
 
 
Fig 3 Stages Three and Four of vigabatrin-associated visual field loss for the Full Field 135 
Point Screening Test with the three zone age-corrected strategy and for the Central 30-2 
Threshold Test.  
For the Full Field 135 Point Screening Test,  represents a ‘seen’ response to the initial 
(dimmest) stimulus luminance;  represents a ‘non-seen’ response to the initial (dimmest) 
stimulus luminance but a ‘seen’ response to the maximum (brightest) stimulus luminance; 
represents a ‘non-seen’ response to the maximum (brightest) stimulus luminance 
For the Central 30-2 Threshold Test, MD indicates Mean Deviation, PSD indicates Pattern 
Standard Deviation and SI indicates Symmetry Index. The symbols , ,  and  indicate the 
probability of the difference between the measured value of sensitivity and the corresponding 
age-corrected normal value, after the general height adjustment, lying within the statistically 
normal range at p<5%, p<2%, p<1% and p<0.5%, respectively 
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Fig 4 Stages Five and Six of vigabatrin-associated visual field loss for the Full Field 135 
Point Screening Test with the three zone age-corrected strategy and for the Central 30-2 
Threshold Test.  
For the Full Field 135 Point Screening Test,  represents a ‘seen’ response to the initial 
(dimmest) stimulus luminance;  represents a ‘non-seen’ response to the initial (dimmest) 
stimulus luminance but a ‘seen’ response to the maximum (brightest) stimulus luminance; 
represents a ‘non-seen’ response to the maximum (brightest) stimulus luminance 
For the Central 30-2 Threshold Test, MD indicates Mean Deviation, PSD indicates Pattern 
Standard Deviation and SI indicates Symmetry Index. The symbols , ,  and  indicate the 
probability of the difference between the measured value of sensitivity and the corresponding 
age-corrected normal value, after the general height adjustment, lying within the statistically 
normal range at p<5%, p<2%, p<1% and p<0.5%, respectively 
 
Fig 5 The Mean Deviation and Pattern Standard Deviation as a function of the ranked 
outcome of the Central 30-2 Threshold Test for each eye of the 99 individuals. The circles 
represent the Mean Deviation and the squares the Pattern Standard Deviation. The black 
symbols represent the outcome from the right eye and the open symbols that from the left eye 
 
 
Fig 6. The two components of the symmetry index. The coloured area comprises the data 
points from one million randomly generated pairs of fields, each of which possesses differing 
within- and between-eye levels of field loss and represents the likelihood of the symmetry 
outcome occurring due to chance at p>0.01. The black circles represent individuals exposed 
to vigabatrin, the vast majority of which lie above the shaded area indicating a high level of 
symmetry. Note the circles in the bottom left hand corner indicate an absence of symmetry 
since the fields are normal and those in the top right corner indicate a high degree of 
symmetry since the fields exhibit advanced loss. The scale on the right hand ordinate 
indicates the level of probability attributable to a random occurrence of symmetry: any circle 
lying within the white region exhibits a p≤0.01 of symmetry occurring due to chance 
 
Fig 7 A case of progressive VAVFL within the central field of each eye, illustrated in terms 
of the Pattern Deviation probability map. The visual fields up to 82 months from onset of 
therapy were obtained using the Central 24-2 Threshold Test and subsequently with the 
Central 30-2 Threshold Test. Vigabatrin was withdrawn after 93 months of therapy. The 
patient remained asymptomatic. MD indicates Mean Deviation and PSD indicates Pattern 
Standard Deviation. The outcome of the Full Field 135 Point Screening Test at 101 months is 
given in Online Resource Fig 5 
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Online Resource Fig 1 Video of the rolling median of the 78 modelled fields from the 87 
individuals who had been exposed to vigabatrin and who had undertaken the Full Field 135 
Point Test with the three zone age-corrected strategy 
 
Online Resource Fig 2 Video of the rolling median of the 90 modelled fields from the 99 
individuals who had been exposed to vigabatrin and who had undertaken the Central 30-2 
Threshold Test 
 
Online Resource Fig 3 Video of the rolling median of the 54 modelled fields from the 63 
individuals who had been exposed to vigabatrin and who had undertaken the combined Full 
Field 135 Point Test with the three zone age-corrected strategy and the Central 30-2 
Threshold Test 
 
Online Resource Fig 4 Video of the rolling median of the 29 modelled fields from the 38 
individuals with no exposure to vigabatrin and who had undertaken the combined Full Field 
135 Point Test with the three zone age-corrected strategy and the Central 30-2 Threshold Test 
 
All v ideo files are available here: https://doi.org/10.6084/m9.figshare.7981592 
 
Online Resource Fig 5 The outcome of the Full Field 135 Point Screening Test at 101 
months for the case shown in Fig 5 together with that of the Central 30-2 Threshold Test 
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